47 related articles for article (PubMed ID: 10997515)
1. Retrospective Evaluation of Melphalan, Vincristine, and Cytarabine Chemotherapy for the Treatment of Relapsed Canine Lymphoma.
Duckett ME; Curran KM; Bracha S; Leeper HJ
J Am Anim Hosp Assoc; 2024 Jan; 60(1):7-14. PubMed ID: 38175982
[TBL] [Abstract][Full Text] [Related]
2. Novel Treatments for Lymphoma.
Thamm DH
Vet Clin North Am Small Anim Pract; 2024 May; 54(3):477-490. PubMed ID: 38199913
[TBL] [Abstract][Full Text] [Related]
3. Oxidative stress in dogs with multicentric lymphoma: Effect of chemotherapy on oxidative and antioxidant biomarkers.
Bottari NB; Munhoz TD; Torbitz VD; Tonin AA; Anai LA; Semolin LM; Jark PC; Bollick YS; Moresco RN; França RT; Lopes ST; Stefani LM; Tinucci-Costa M; Da Silva AS
Redox Rep; 2015; 20(6):267-74. PubMed ID: 26274787
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiles associated with early relapse during first remission induction in canine multicentric high-grade B-cell lymphoma.
Toyoda H; Tani A; Goto-Koshino Y; Motegi T; Sakamoto M; Mochizuki T; Harada K; Kobayashi T; Setoguchi A; Shizuta Y; Mizuno T; Irie M; Nakamichi J; Tsujimoto H; Ohmi A; Fukuoka R; Nakamura Y; Tomiyasu H
J Vet Med Sci; 2024 Jan; 86(1):18-27. PubMed ID: 37952972
[TBL] [Abstract][Full Text] [Related]
5. Vincristine-induced adverse events related to body weight in dogs treated for lymphoma.
Sztukowski KE; Yaufman Z; Cook MR; Aarnes TK; Husbands BD
J Vet Intern Med; 2024; 38(3):1686-1692. PubMed ID: 38563346
[TBL] [Abstract][Full Text] [Related]
6. Individualized chemotherapy drug dose escalation in dogs with multicentric lymphoma.
Siewert JM; Gustafson DL; Weishaar KM; Galloway AM; Thamm DH
J Vet Intern Med; 2023; 37(6):2402-2409. PubMed ID: 37787577
[TBL] [Abstract][Full Text] [Related]
7. Long-term remission and survival in dogs with high-grade, B cell lymphoma treated with chemotherapy with or without sequential low-dose rate half-body irradiation.
Best MP; Straw RC; Gumpel E; Fry DR
J Vet Intern Med; 2023; 37(6):2368-2374. PubMed ID: 37700548
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical outcome of hypercalcemia of malignancy and concurrent azotemia in dogs with lymphoma.
Strumpf AA; Selmic L; Husbands B
J Vet Intern Med; 2024; 38(1):308-315. PubMed ID: 38131263
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of factors influencing survival time in 77 dogs with lymphoma.
Jeong SY
Open Vet J; 2023 Sep; 13(9):1124-1134. PubMed ID: 37842100
[TBL] [Abstract][Full Text] [Related]
11. Review of Canine Lymphoma Treated with Chemotherapy-Outcomes and Prognostic Factors.
Bennett P; Williamson P; Taylor R
Vet Sci; 2023 May; 10(5):. PubMed ID: 37235425
[TBL] [Abstract][Full Text] [Related]
12. Mott Cell Differentiation in Canine Multicentric B Cell Lymphoma with Cross-Lineage Rearrangement and Lineage Infidelity in a Dog.
Kim WS; Song KH; Bae H; Yu D; Song JH
Vet Sci; 2022 Oct; 9(10):. PubMed ID: 36288162
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Proliferative Activity of Diffuse Large B-Cell Lymphoma (DLBCL) in Dogs with Respect to Patient Eligibility for Anthracycline-Based Chemotherapy.
Klimiuk P; Łopuszyński W; Bulak K; Brzana A
Animals (Basel); 2021 Apr; 11(4):. PubMed ID: 33924252
[TBL] [Abstract][Full Text] [Related]
14. Welfare-Adjusted Life Years (WALY): A novel metric of animal welfare that combines the impacts of impaired welfare and abbreviated lifespan.
Teng KT; Devleesschauwer B; Maertens De Noordhout C; Bennett P; McGreevy PD; Chiu PY; Toribio JLML; Dhand NK
PLoS One; 2018; 13(9):e0202580. PubMed ID: 30208045
[TBL] [Abstract][Full Text] [Related]
15. Small-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse Chemotherapeutics.
Botham RC; Roth HS; Book AP; Roady PJ; Fan TM; Hergenrother PJ
ACS Cent Sci; 2016 Aug; 2(8):545-59. PubMed ID: 27610416
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.
Parsons-Doherty M; Poirier VJ; Monteith G
Can Vet J; 2014 Feb; 55(2):175-80. PubMed ID: 24489398
[TBL] [Abstract][Full Text] [Related]
17. Clonality and phenotyping of canine lymphomas before chemotherapy and during remission using polymerase chain reaction (PCR) on lymph node cytologic smears and peripheral blood.
Thilakaratne DN; Mayer MN; MacDonald VS; Jackson ML; Trask BR; Kidney BA
Can Vet J; 2010 Jan; 51(1):79-84. PubMed ID: 20357946
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study.
Baskin CR; Couto CG; Wittum TE
J Am Anim Hosp Assoc; 2000; 36(5):404-9. PubMed ID: 10997515
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
